Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials

Background Primaquine (PQ) actively clears mature Plasmodium falciparum gametocytes but in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals can cause hemolysis. We assessed the safety of low-dose PQ in combination with artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) in G6PDd African males with asymptomatic P. falciparum malaria. Methods and findings In Burkina Faso, G6PDd adult males were randomized to treatment with AL alone (n = 10) or with PQ at 0.25 (n = 20) or 0.40 mg/kg (n = 20) dosage; G6PD-normal males received AL plus 0.25 (n = 10) or 0.40 mg/kg (n = 10) PQ. In The Gambia, G6PDd adult males and boys received DP alone (n = 10) or with 0.25 mg/kg PQ (n = 20); G6PD-normal males received DP plus 0.25 (n = 10) or 0.40 mg/kg (n = 10) PQ. The primary study endpoint was change in hemoglobin concentration during the 28-day follow-up. Cytochrome P-450 isoenzyme 2D6 (CYP2D6) metabolizer status, gametocyte carriage, haptoglobin, lactate dehydrogenase levels and reticulocyte counts were also determined. In Burkina Faso, the mean maximum absolute change in hemoglobin was -2.13 g/dL (95% confidence interval [CI], -2.78, -1.49) in G6PDd individuals randomized to 0.25 PQ mg/kg and -2.29 g/dL (95% CI, -2.79, -1.79) in those receiving 0.40 PQ mg/kg. In The Gambia, the mean maximum absolute change in hemoglobin concentration was -1.83 g/dL (95% CI, -2.19, -1.47) in G6PDd individuals receiving 0.25 PQ mg/kg. After adjustment for baseline concentrations, hemoglobin reductions in G6PDd individuals in Burkina Faso were more pronounced compared to those in G6PD-normal individuals receiving the same PQ doses (P = 0.062 and P = 0.022, respectively). Hemoglobin levels normalized during follow-up. Abnormal haptoglobin and lactate dehydrogenase levels provided additional evidence of mild transient hemolysis post-PQ. Conclusions Single low-dose PQ in combination with AL and DP was associated with mild and transient reductions in hemoglobin. None of the study participants developed moderate or severe anemia; there were no severe adverse events. This indicates that single low-dose PQ is safe in G6PDd African males when used with artemisinin-based combination therapy. Trial registration Clinicaltrials.gov NCT02174900 Clinicaltrials.gov NCT02654730

[1]  J. Ndiaye,et al.  Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Hannah C. Slater,et al.  Mathematical Modelling to Guide Drug Development for Malaria Elimination , 2017, Trends in parasitology.

[3]  A. Dicko,et al.  Comparison of molecular quantification of Plasmodium falciparum gametocytes by Pfs25 qRT-PCR and QT-NASBA in relation to mosquito infectivity , 2016, Malaria Journal.

[4]  B. Ngasala,et al.  Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania , 2016, Malaria Journal.

[5]  A. Dicko,et al.  Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. , 2016, The Lancet. Infectious diseases.

[6]  F. Nosten,et al.  Single Low Dose Primaquine (0.25mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects , 2016, PloS one.

[7]  T. Bousema,et al.  Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial , 2016, BMC Medicine.

[8]  J. Rubio,et al.  Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial , 2016, Malaria Journal.

[9]  I. Elyazar,et al.  Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia , 2015, BMC Medicine.

[10]  Emmaculate Lum,et al.  Malarial Anaemia and Anaemia Severity in Apparently Healthy Primary School Children in Urban and Rural Settings in the Mount Cameroon Area: Cross Sectional Survey , 2015, PloS one.

[11]  T. Bousema,et al.  The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial , 2015, Trials.

[12]  B. Tekwani,et al.  Differential CYP 2D6 Metabolism Alters Primaquine Pharmacokinetics , 2015, Antimicrobial Agents and Chemotherapy.

[13]  T. Bousema,et al.  Glucose-6-Phosphate Dehydrogenase Status and Risk of Hemolysis in Plasmodium falciparum-Infected African Children Receiving Single-Dose Primaquine , 2014, Antimicrobial Agents and Chemotherapy.

[14]  J. Crump,et al.  Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria , 2014, PloS one.

[15]  T. Bousema,et al.  Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. , 2014, The Lancet. Infectious diseases.

[16]  J. Swen,et al.  Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. , 2014, Current drug metabolism.

[17]  David L. Smith,et al.  Modeling Within-Host Effects of Drugs on Plasmodium falciparum Transmission and Prospects for Malaria Elimination , 2014, PLoS Comput. Biol..

[18]  Q. Cheng,et al.  G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests , 2013, Malaria Journal.

[19]  D. Caridha,et al.  The metabolism of primaquine to its active metabolite is dependent on CYP 2D6 , 2013, Malaria Journal.

[20]  D. Caridha,et al.  An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolines. , 2013, The American journal of tropical medicine and hygiene.

[21]  L. Okell,et al.  Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. , 2013, The Journal of infectious diseases.

[22]  T. Bousema,et al.  Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda , 2013, BMJ Open.

[23]  N. White Primaquine to prevent transmission of falciparum malaria. , 2013, The Lancet. Infectious diseases.

[24]  I. Elyazar,et al.  Randomized, Open-Label Trial of Primaquine against Vivax Malaria Relapse in Indonesia , 2012, Antimicrobial Agents and Chemotherapy.

[25]  T. Bousema,et al.  Rationale for short course primaquine in Africa to interrupt malaria transmission , 2012, Malaria Journal.

[26]  A. Gaedigk,et al.  CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes. , 2012, Pharmacogenetics and genomics.

[27]  Q. Bassat,et al.  Tolerability and Safety of Primaquine in Papua New Guinean Children 1 to 10 Years of Age , 2012, Antimicrobial Agents and Chemotherapy.

[28]  S. Hoffman,et al.  Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue , 2011, Proceedings of the National Academy of Sciences.

[29]  S. Duparc,et al.  Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials , 2011, Malaria Journal.

[30]  T. Déirdre Hollingsworth,et al.  The Potential Contribution of Mass Treatment to the Control of Plasmodium falciparum Malaria , 2011, PloS one.

[31]  Teun Bousema,et al.  Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination , 2011, Clinical Microbiology Reviews.

[32]  David Schellenberg,et al.  A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics , 2011, PLoS medicine.

[33]  Elizabeth Ashley,et al.  Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial , 2010, The Lancet. Infectious diseases.

[34]  Teun Bousema,et al.  Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs , 2010 .

[35]  T. Bousema,et al.  In Tanzania, Hemolysis after a Single Dose of Primaquine Coadministered with an Artemisinin Is Not Restricted to Glucose-6-Phosphate Dehydrogenase-Deficient (G6PD A−) Individuals , 2010, Antimicrobial Agents and Chemotherapy.

[36]  F. Ou,et al.  Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine , 2010, Malaria Journal.

[37]  T. Bousema,et al.  Substantial Contribution of Submicroscopical Plasmodium falciparum Gametocyte Carriage to the Infectious Reservoir in an Area of Seasonal Transmission , 2009, PloS one.

[38]  A. Dicko,et al.  Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria. , 2009, The American journal of tropical medicine and hygiene.

[39]  Paul Garner,et al.  Artemisinin-based combination therapy for treating uncomplicated malaria. , 2009, The Cochrane database of systematic reviews.

[40]  S. Blair,et al.  [Therapeutic efficacy of a regimen of artesunate-mefloquine-primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development]. , 2009, Biomedica : revista del Instituto Nacional de Salud.

[41]  Pardis C Sabeti,et al.  Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility , 2009, European Journal of Human Genetics.

[42]  Teun Bousema,et al.  Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials , 2008, Malaria Journal.

[43]  A. Gaedigk,et al.  The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.

[44]  H. Babiker,et al.  A Randomized Open-Label Trial of Artesunate- Sulfadoxine-Pyrimethamine with or without Primaquine for Elimination of Sub-Microscopic P. falciparum Parasitaemia and Gametocyte Carriage in Eastern Sudan , 2007, PloS one.

[45]  T. Bousema,et al.  Primaquine Clears Submicroscopic Plasmodium falciparum Gametocytes that Persist after Treatment with Sulphadoxine-Pyrimethamine and Artesunate , 2007, PloS one.

[46]  Ernest Beutler,et al.  Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. , 2007, The American journal of tropical medicine and hygiene.

[47]  S. Hoffman,et al.  Primaquine therapy for malaria. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Petra Schneider,et al.  Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. , 2004, Molecular and biochemical parasitology.

[49]  N. Gogtay,et al.  A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India , 2004, Annals of tropical medicine and parasitology.

[50]  Nicholas J. White,et al.  Activities of Artesunate and Primaquine against Asexual- and Sexual-Stage Parasites in Falciparum Malaria , 2004, Antimicrobial Agents and Chemotherapy.

[51]  P. Kager,et al.  CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone–proguanil against falciparum malaria in Vietnam , 2004, Tropical medicine & international health : TM & IH.

[52]  Y. Suputtamongkol,et al.  The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia. , 2003, The American journal of tropical medicine and hygiene.

[53]  R. Price,et al.  Factors contributing to anemia after uncomplicated falciparum malaria. , 2001, The American journal of tropical medicine and hygiene.

[54]  C. Drakeley,et al.  Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. , 2001, The Journal of infectious diseases.

[55]  K. Yip Antimalarial work in China: a historical perspective. , 1998, Parassitologia.

[56]  S. Hoffman,et al.  Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. , 1995, The Journal of infectious diseases.

[57]  E. Beutler,et al.  Frequency of glucose-6-phosphate dehydrogenase (G6PD) mutations in Chinese, Filipinos, and Laotians from Hawaii , 1993, Human Genetics.

[58]  P. Reeve,et al.  Acute intravascular haemolysis in Vanuatu following a single dose of primaquine in individuals with glucose-6-phosphate dehydrogenase deficiency. , 1992, The Journal of tropical medicine and hygiene.

[59]  K. Thimasarn Current measures of containment of multi-drug resistant falciparum malaria in Thailand. , 1992, The Southeast Asian journal of tropical medicine and public health.

[60]  R S Galen,et al.  Application of the predictive value model in the analysis of test effectiveness. , 1982, Clinics in laboratory medicine.

[61]  K. K. Khoo The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. , 1981, Annals of tropical medicine and parasitology.

[62]  T. Harinasuta,et al.  EFFECT OF PRIMAQUINE ON GAMETOCYTES OF PLASMODIUM FALCIPARUM IN THAILAND , 1980, The Lancet.

[63]  R. Galen,et al.  The predictive value of serum haptoglobin in hemolytic disease. , 1980, JAMA.

[64]  J. Kaplan,et al.  International Committee for Standardization in Haematology: Recommended Screening Test for Glucose‐6‐Phosphate Dehydrogenase (G‐6‐PD) Deficiency , 1979, British journal of haematology.

[65]  H. Notopuro,et al.  Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.

[66]  R. J. Dern,et al.  The hemolytic effect of primaquine. IV. The relationship of cell age to hemolysis. , 1954, The Journal of laboratory and clinical medicine.

[67]  E. Ashley,et al.  Primaquine: the risks and the benefits , 2014, Malaria Journal.

[68]  A. Kleinman,et al.  Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria , 2013 .

[69]  Q. Cheng,et al.  PD testing in support of treatment and elimination of malaria : recommendations for evaluation of G 6 PD tests , 2013 .

[70]  A. Kondrashin,et al.  [Widespread use of primaquine for control of Plasmodium vivax epidemics in a population with varying degrees of G6PD deficiency]. , 2010, Meditsinskaia parazitologiia i parazitarnye bolezni.

[71]  R. J. Dern,et al.  The hemolytic effect of primaquine V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. , 1981, The Journal of laboratory and clinical medicine.

[72]  D. Clyde Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. , 1981, Bulletin of the World Health Organization.

[73]  A. Gehani,et al.  [G6PD deficiency]. , 1974, Xianggang hu li za zhi. The Hong Kong nursing journal.

[74]  Resistance to Antimalarials Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group. , 1973, World Health Organization technical report series.

[75]  E. Beutler,et al.  Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. , 1968, Blood.

[76]  K. Abeyaratne,et al.  Sensitivity to primaquine in Ceylonese children due to deficiency of erythrocytic glucose-6-phosphate dehydrogenase. , 1968, The Ceylon medical journal.

[77]  D. Clyde Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika. , 1962, Bulletin of the World Health Organization.

[78]  R. W. Burgess,et al.  The effect of a single dose of primaquine on the gametocytes, gametogony and sporogony of Laverania falciparum. , 1961, Bulletin of the World Health Organization.

[79]  A. Tarlov,et al.  Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. , 1960, Bulletin of the World Health Organization.

[80]  A. Tarlov,et al.  Methaemoglobin reduction test: a new, simple, in vitro test for identifying primaquine-sensitivity. , 1960, Bulletin of the World Health Organization.

[81]  L. Bruce-Chwatt Malaria research and eradication in the USSR. A review of Soviet achievements in the field of malariology. , 1959, Bulletin of the World Health Organization.

[82]  R. J. Dern,et al.  The hemolytic effect of primaquine. V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. , 1955, The Journal of laboratory and clinical medicine.

[83]  C. Clayman,et al.  Toxicity of primaquine in Negroes. , 1952, Journal of the American Medical Association.